ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study
| Autor: | Kenneth Cusi, Ralph A. DeFronzo, Amalia Gastaldelli, Leonard C. Glass, Eugenio Cersosimo, R. Petz, Rachele Berria |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Internal medicine Diabetes mellitus medicine 030304 developmental biology 0303 health sciences Glucose tolerance test medicine.diagnostic_test business.industry Insulin medicine.disease 3. Good health Postprandial Basal (medicine) business Pioglitazone medicine.drug |
| Zdroj: | Clinical Endocrinology. 73:339-345 |
| ISSN: | 0300-0664 |
| DOI: | 10.1111/j.1365-2265.2010.03811.x |
| Popis: | Summary Objectives By using tracer techniques, we explored the metabolic mechanisms by which pioglitazone treatment for 16 weeks improves oral glucose tolerance in patients with type 2 diabetes when compared to subjects without diabetes. Methods In all subjects, before and after treatment, we measured rates of tissue glucose clearance (MCR), oral glucose appearance (RaO) and endogenous glucose production (EGP) during a (4-h) double tracer oral glucose tolerance test (OGTT) (1-14C-glucose orally and 3-3H-glucose intravenously). Basal hepatic insulin resistance index (HepIR) was calculated as EGPxFPI. β-cell function was assessed as the incremental ratio of insulin to glucose (ΔI/ΔG) during the OGTT. Results Pioglitazone decreased fasting plasma glucose concentration (10·5 ± 0·7 to 7·8 ± 0·6 mm, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text